JPH10120583A - Antiallergic agent, chemical mediator liberation suppressant and antiallergic cosmetic, medicine and food comprising the sam - Google Patents

Abstract

PROBLEM TO BE SOLVED: To prepare the subject agent having high safety without any adverse effects by using an extract of a specific plan having antillergic actions based on chemical mediator liberation inhibiting actions from a mastycyute and a basocyte as an active ingredient. SOLUTION: This therapeutic agent comprises one or more selected from an extract from a plant of the genus Coix [preferably Coix lachryma-jobi var. ma-yuen (Roman.) Stapf.], an extract from a plant of the family Saururaceae [preferably Huttuynia cordate Tedicineunb. Saururus chineses (Lour.) Baill. or Hottuynia Herba] and an extract from a plant of the geus Tilia [preferably a flower of Tilia japonica (Miq.) Simonk.] as an active ingredient. The chemical mediator is preferably histamine, serotonin or leukotriene. The daily dose of the plant extract when utilized as a medicine is 5-500mg expressed in terms of dry weight in the case of oral administration. The concentration thereof when formulated in a food or a cosmetic is preferably 0.001-20wt.%.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an allergic reaction caused by suppressing the release of chemical mediators such as histamine, serotonin and leukotriene released from mast cells and / or basophils. The present invention relates to drugs for preventing or treating diseases, cosmetics and foods containing these as active ingredients.

[0002]

2. Description of the Related Art Chemical mediators such as histamine, serotonin, and leukotriene are released from mast cells and basophils by allergen inflammation stimulation, resulting in increased vascular permeability, smooth muscle contraction, increased mucus secretion, and enhanced immune cell migration. Allergic reaction occurs.

[0003] Therefore, the inflammation of the therapeutic agent by allergic reactions, have antihistamine is used predominantly H ₁ receptor inhibitor. However, the currently used antihistamines have a central inhibitory effect, and there is a problem that side effects such as drowsiness and dizziness and malaise occur easily.

[0004]

SUMMARY OF THE INVENTION An object of the present invention is to provide a highly safe antiallergic agent which does not cause the above-mentioned side effects.

[0005]

Means for Solving the Problems As a means for solving the above problems, the present inventors have widely screened substances having an anti-allergic effect from natural products, and as a result, it has been found that mast cells and basophils are extracted from specific plant extracts. They have found that they have an antiallergic effect based on the inhibitory effect of chemical mediator release from spheres, and have completed the present invention.

[0006] That is, the antiallergic agent of the present invention comprises a histamine from mast cells and / or basophils of one or more plant extracts selected from the genus Adler, the Asteraceae and the linden plants. , Serotonin, leukotriene and the like.

[0007]

BEST MODE FOR CARRYING OUT THE INVENTION The plant of the genus Juzudama used in the present invention is a plant of the Gramineae family, and is a plant of the genus Gramineae.
x lachryma - jobi L.) and its varieties Onixuzuma ( Coix lachryma - jobi var. maxima Makino) and Nagaminozuzuma ( Coix lachryma - jobi var. stenocarpa Sta)
pf.), a cultivar of Juzudama ( Coix lach
ryma - jobi var. ma - yuen (Roman.) Stapf., Coix lachryma
-. Jobi var frumentacea Makino, Coix lachryma -. Jobi
var. ma - yuen Roman.). Among the above-mentioned plants, the seeds other than the barley seed coat are crude drugs called yoquinin, which are used in Chinese medicine for diuresis, inflammation, and drainage.

[0008] The extraction site for obtaining the extract of the plant belonging to the genus Jujuda is not particularly limited, and the whole plant or leaf, stem, root,
An extract can be obtained using one or more selected from flowers and seeds. Among them, extracts obtained from adlay seeds are particularly preferred from the viewpoint of antiallergic effect and chemical mediator release inhibitory effect.

[0009] In the present invention, the swelling family ( Saururace)
ae ), as a plant of the genus Dokudami ( Houttu
ynia cordata Thunb.) and the genus Hangeshaw ( Saururus chinensis (Lour.) Baill.). The above-ground part of the flowering period of the peony is a crude drug called jujuk, which is known to have diuretic, cardiotonic and antibacterial effects. Hangeshaw has the same pharmacological activity as Dokudami, and is a crude drug called Sanshikusa.

[0010] Regarding the dokudami, it has been disclosed that a bath preparation containing green juice of dokudami grass as a main component has a therapeutic effect on atopic dermatitis which is a kind of allergic disease (Japanese Patent Application Laid-Open No. Hei 7-277947). ). However, the therapeutic effect of Acer dermatitis on atopic dermatitis is based on an antibacterial effect, and there is no disclosure suggesting an antiallergic effect and an inhibitory effect on release of a chemical mediator of the Acer dermis extract.

There is no particular limitation on the site of extraction for obtaining the extract of Pteridophyta, and the extract may be obtained using one or more selected from whole plants or leaves, stems, roots, flowers, and seeds. Can be. Among them, an extract obtained from the above-ground part of the flowering phase is most preferable from the viewpoint of the antiallergic effect and the effect of suppressing the release of the chemical mediator.

The linden plant used in the present invention is a kind of linden plant ( Tiliaceae ),
(Tilia americana L.), Tilia cordata (Tilia cordata
Mill., Tilia ulmifolia Scop., Tilia parvifolia Eh
rh.) Tilia europaea L., Tilia japonica (Miq.) Simonk., Hera tree ( Tiliaki
usiana Makino et Shiras.), Oba linden (Tilia
maximowicziana Shiras.), Bodaiju ( Tilia miquelia )
na Maxim.), Natsubodaiju ( Tilia platyphyllos Sco
p., Tilia grandifolia Ehrh.) and the like.

The linden plants such as bollige are widely used as a folk medicine in Europe. The essential oil obtained from the dried inflorescence is used as a sweat, an antispasmodic or a bathing agent. It has been used for burns and wound healing.

The extraction site of the extract of the linden plant is not particularly limited, but the bark and its mucus, fruit,
Examples include seeds, flowers, branches and leaves, and among them, extracts of linden flowers are most preferred from the viewpoint of antiallergic action and chemical mediator release inhibitory action.

When an extract is obtained from these plants, the plants can be extracted raw or in a dry state. However, from the viewpoint of odor and storage stability, it is necessary to use the dried product as it is or after pulverizing it. preferable.

Solvents for obtaining these plant extracts include water, ethanol, methanol, isopropanol,
Alcohols such as isobutanol, n-hexanol, methylamyl alcohol, 2-ethylbutanol, n-octyl alcohol, glycerin, ethylene glycol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, propylene glycol, propylene glycol monomethyl ether, propylene Glycol monoethyl ether, triethylene glycol,
Polyhydric alcohols such as 1,3-butylene glycol and hexylene glycol or derivatives thereof, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone, and methyl-n-propyl ketone; esters such as ethyl acetate and isopropyl acetate; ethyl ether One or a mixture of two or more polar solvents such as ethers such as isopropyl ether, n-butyl ether and the like can be suitably used, but there is no particular limitation. Or petroleum ether, n-hexane, n-pentane, n-butane, n-octane,
One or more mixed solvents of non-polar solvents such as aliphatic hydrocarbons such as cyclohexane, carbon tetrachloride, chloroform, dichloromethane, trichloroethylene, benzene, and toluene can also be suitably used.

The solvent from which the extract of the plant of the genus Jujuda is obtained is not particularly limited as long as it is the above-mentioned solvent, but a polar solvent is preferred in view of its antiallergic action and the action of inhibiting the release of chemical mediators.
One or a mixture of two or more of 3-butylene glycol and water is preferable, and among them, a solvent using water alone as the extraction solvent is most preferable.

The solvent for obtaining the extract of Pteridophyta is not particularly limited as long as it is the above-mentioned solvent. However, a polar solvent is preferred from the viewpoint of antiallergic action and action of suppressing chemical mediator release, and ethanol, glycols, One or more mixed solvents of water are preferred,
Among them, those using a mixed solvent of one or more selected from glycols such as glycerin and 1,3-butylene glycol and water are most preferable.

The solvent from which the extract of the linden plant is obtained is not particularly limited as long as it is the above-mentioned solvent, but a polar solvent is preferred in view of the antiallergic action and the action of inhibiting the release of a chemical mediator. One or more mixed solvents of water are preferred,
Among them, those using a mixed solvent of one or more selected from glycols such as glycerin and 1,3-butylene glycol and water are most preferable.

The ratio of the plant to the solvent at the time of extraction is not particularly limited.
It is preferably 0 times by weight, especially 5 to 100 times by weight in terms of extraction operation and efficiency. The extraction temperature is conveniently in the range from room temperature to the boiling point of the solvent under normal pressure, and the extraction time varies depending on the extraction temperature and the like, but is preferably in the range of 2 hours to 2 weeks.

The plant extract thus obtained can be used as it is, or subjected to deodorization, purification, etc. within a range that does not lose the antiallergic effect and the inhibitory effect of chemical mediator release. It is also possible to mix them afterwards, and further, they may be used as fractions using column chromatography or the like. Further, these extracts, deodorized, purified, and fractionated products can be dried by removing the solvent therefrom, and further provided in the form of a solution solubilized in a solvent such as alcohol or in the form of an emulsion. can do.

The antiallergic agent and the chemical mediator release inhibitor according to the present invention can be added to and blended with foods, pharmaceuticals, cosmetics and the like.

Pharmaceuticals can be added to oral preparations, external preparations, injections, inhalants, nasal drops, eye drops, etc. Depending on the method of use, tablets, liquids, injections, ointments, creams, lotions, etc. , Aerosols, suppositories and the like. Excipients, bases,
Emulsifiers, stabilizers, dissolution aids, flavoring agents, preservatives, fragrances, coloring agents, coating agents and the like can be appropriately compounded. The effect can be further enhanced by using with other anti-inflammatory and anti-allergic raw materials such as glycyrrhizic acids, water-soluble azulene, diphenhydramine hydrochloride, dl-α-tocopherol and its derivatives, vitamins B ₂ and B _{6 and the} like. . In formulating, one kind of plant extract may be used.
A synergistic effect can be expected by mixing and using extracts of more than one kind of plant.

In foods, oral compositions such as gums and candies, fish paste products such as kamaboko and chikuwa, livestock products such as sausage and ham, Western confectionery, Japanese confectionery, noodles such as fresh noodles and boiled noodles, and sauces It can be used as a general food and drink dosage form such as seasonings such as soy sauce and sauce, pickles, side dishes, and soft drinks. At this time, various components generally used in foods, such as sugar, condensed milk, flour, shortening, salt, glucose, egg, butter, margarine, starch syrup, calcium, iron, and the like, as long as the effects of the present invention are not impaired. It can be blended with seasonings and spices and used in combination.

The cosmetic can be in any form such as cream, ointment, lotion, emulsion, solid, powder, etc., basic cosmetics such as lotion, emulsion, serum, moisturizing cream, sunscreen cream , Sun care lotion, sun care oil, sun care products such as carmine lotion,
Makeup cosmetics such as foundation, eyeliner, mascara, eye color, teak color, lipstick, facial cleanser, body shampoo, hair shampoo, etc., rinse, treatment, hair cream, hair oil, hair styling etc. It can be used for applications such as ingredients, perfumes, deodorants and antiperspirants. At this time, various components generally used in cosmetics such as avocado oil, palm oil, peanut oil, and the like, as long as the effects of the present invention are not impaired.
Rice bran oil, jojoba oil, orange roughy oil, macadamia nut oil, squalane, evening primrose oil, sesame oil, sunflower oil, safflower oil, carola oil, carnauba wax, paraffin wax, lanolin, diisostearyl malate, isostearyl alcohol , Oils such as liquid paraffin, humectants such as glycerin, diglycerin, polyglycerin, sorbit, polyethylene glycol, 1,3-butylene glycol, collagen, hyaluronic acid, vitamin A such as vitamin A oil, retinol, retinol acetate, riboflavin, vitamin B ₂ such as riboflavin butyrate, vitamin B ₆ such as pyridoxine hydrochloride, L- ascorbic acid, magnesium L- ascorbyl phosphate, vitamin C such as sodium L- ascorbate, calcium pantothenate, D- pan Pantothenic acids such as totenyl alcohol, pantothenyl ethyl ether, and acetyl pantothenyl ethyl ether; vitamin Ds such as ergocalciferol and cholecalciferol; nicotinic acids such as nicotinic acid, nicotinamide and benzyl nicotinate;
Vitamin E such as α-tocopherol and tocopherol acetate, vitamin P such as vitamin P and biotin, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid, and 2-hydroxy-4- Benzophenone derivatives such as sodium methoxybenzophenone-5-sulfonate; paraaminobenzoic acid derivatives such as paraaminobenzoic acid, ethyl paraaminobenzoate and octyl paradimethylaminobenzoate; 2-ethylhexyl paramethoxycinnamate, mono-2-diparamethoxycinnamate Methoxycinnamic acid derivatives such as glyceryl ethylhexanoate, salicylic acid derivatives such as octyl salicylate and myristyl salicylate, urocanic acid, 4-tert-butyl-4'-methoxydibenzoylmethane, 2- (2'-hydroxy-5'- Methylphenyl)
UV absorbers such as benzotriazole, natural plant polysaccharides such as guar gum, locust bean gum, carrageenan, quince seed, pectin, and mannan; microbial natural polysaccharides such as xanthan gum, dextran, curdlan, hyaluronic acid, gelatin, casein , Albumin, collagen and other animal polymers, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose and other semi-synthetic polymers, soluble starch, carboxymethyl starch, and methylstarch and other semi-synthetic polymers , Propylene glycol alginate,
Alginate-based semisynthetic polymers such as alginate, synthetic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium polyacrylate, and polyethylene oxide; and water-soluble polymers such as bentonite, laponite, and colloidal alumina. Polymers, antioxidants such as dibutylhydroxytoluene, butylhydroxyanisole, and gallic acid esters, higher fatty acid soaps, alkyl sulfates, polyoxyethylene alkyl ether sulfates, acylmethyl taurine salts, alkyl ether phosphate salts, acyl Anionic surfactants such as amino acid salts, alkyltrimethylammonium chloride, dialkyldimethylammonium chloride,
Cationic surfactants such as benzalkonium chloride; amphoteric surfactants such as betaine alkyldimethylaminoacetate, betaine alkylamidodimethylaminoacetate, and 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine; Surfactants such as ethylene nonionic surfactant, alcohol ester nonionic surfactant, etc., sequestering agents such as sodium ethylenediaminetetraacetate, sodium polyphosphate, citric acid, sodium metaphosphate, succinic acid, gluconic acid, placenta Whitening agents such as extracts, soybean arbor extract, glutathione, kojic acid and its derivatives, hydroquinones and their derivatives such as hydroquinone glycosides, glycyrrhizic acid,
Anti-inflammatory agents such as glycyrrhetinic acid, allantoin, azulene, hydrocortisone, ε-aminocaproic acid, astringents such as zinc oxide, allantoin hydroxyaluminum, aluminum chloride, tannic acid, citric acid, and lactic acid; cooling agents such as menthol and camphor; Estradiol,
Sebum depressants such as estrone and ethinyl estradiol, exfoliants and dissolving agents such as salicylic acid and resorcinol, α
-Hydroxy acids and the like can be blended. Still other anti-inflammatory,
Antiallergic material for example, it is also possible to further increase the effect thereof by using glycyrrhizin acids, water-soluble azulene, diphenhydramine hydrochloride, dl-alpha-tocopherol and its derivatives, together with vitamin B ₂ and B _6, and the like. In preparation, a single plant extract or the like may be used, but a synergistic effect can be expected by using a mixture of two or more plant extracts.

The dosage of the plant extract when used as a medicament varies greatly depending on the type of plant used, the degree of purification, the age and symptoms of the patient, etc., but in general, in the case of oral administration, the dry weight Range from 5 to 500 mg / day. When blended in foods and cosmetics, the concentration is preferably in the range of 0.001 to 20% by weight in view of the effect, the scent when added, and the color tone.

[0027]

DESCRIPTION OF THE PREFERRED EMBODIMENTS The features of the present invention will be described in detail with reference to embodiments.

Prior to the description of the examples, a method for preparing the plant extract used in each example will be described. 100 g of the dried product from a specific part of the plant was immersed in 1000 g of a solvent at room temperature for 7 days, and the supernatant was filtered. Table 1 shows the extraction site and solvent for each plant.

[0029]

[Table 1]

The inhibitory effect of the plant extracts of Examples 1 to 3 on histamine release was determined using rat-derived basophil leukemia cells (RBL-
Evaluation was performed using an antiallergic test method using histamine released from 2H3) as an index.

RBL-2H3 was added to a 48-well plate by 2.5
Cells were seeded at a density of 10 ⁵ cells / well, cultured for 24 hours (carbon dioxide 5%, 37 ° C.), and then released with a solvent (117).
mM, NaCl, 5.4 mM, KCl, 2.0 mM, Ca
_{Cl 2, 0.8mM, MgSO 4,} 5.6mM, D- glucose, 25m, N-2- hydroxyethylpiperazine--N'-2-ethanesulfonic acid buffer and 1 mg / m
1, a solution containing bovine serum albumin, pH 7.7) 500
After washing twice with μl, the reaction solution was added and the cells were cultured at 37 ° C. for 60 minutes. 100 μl of the extracellular solution was taken out, and the remaining solution was removed by suction. Then, 0.2% Triton X-10
0 was added at 300 μl / well, and after 20 minutes, 100 μl of cell lysate (intracellular solution) was taken out. An unreacted reaction solution was also taken out of the extracellular solution and the intracellular solution by 100 μl each and used as a control. Table 2 shows the composition of the reaction solution.

[0032]

[Table 2]

The amount of histamine as a chemical mediator in the extracellular fluid, intracellular fluid and control thus obtained was determined by a post-column method using a high performance liquid chromatograph (immune experiment operation method). 2. Shunsuke Migita, Susumu Konda, Yu Honjo, Toshiyuki Hamaoka, edited by Nankodo, 1995, p. 1037). The histamine release rate and the histamine release inhibition rate were calculated using Equations 1 and 2. Table 3 shows the histamine release inhibition rates of Examples 1 to 3.

[0034]

(Equation 1) In Formula 1, A represents the amount of histamine in the intracellular fluid, Bin and Bout represent the amount of histamine in the control intracellular fluid and extracellular fluid, and C represents the amount of histamine in the extracellular fluid.

[0035]

(Equation 2) In Formula 2, D represents the histamine release rate at the time of sample addition, E represents the histamine release rate in the positive control, and F represents the histamine release rate in the negative control.

[0036]

[Table 3]

As shown in Table 3, it is apparent that the plant extracts of Examples 1 to 3 exhibited a histamine release inhibitory action of 60% or more, and inhibited histamine release.

Examples 4 to 6 Water-in-oil ointment (1) Beeswax 3.0 (% by weight) (2) Hydrogenated lanolin 8.0 (3) Squalane 34.0 (4) Solid paraffin 2.0 (5) ) Microcrystalline wax 9.0 (6) White petrolatum 5.0 (7) Hexyldecyl adipate 12.8 (8) Sorbitan sesquioleate 3.5 (9) Polyoxyethylene (50) hydrogenated castor oil 1.0 (10) Glycerin 10.0 (11) Purified water 10.0 (12) Ethanol 1.0 (13) Crude drug and plant extract of Examples 1-3 0.5 (14) Methyl paraoxybenzoate 0.2 Production method The oil phase of (1) to (9) and the aqueous phase components of (10) and (11) are each heated to 75 ° C. and mixed and homogenized, and then the aqueous phase is added to the oil phase and emulsified. After cooling, the mixture obtained by mixing (12) to (14) at 40 ° C. and homogenizing is kneaded.

The water-in-oil ointments of Examples 4 to 6 were mixed with 17 to 30
A two-year-old woman with atopic dermatitis was applied twice daily to the affected area twice a day in the morning and evening, and the results shown in Table 4 were obtained regarding the improvement of symptoms. At the same time, an ointment containing no plant extract was prepared. During the period of use,
The use of other antiallergic drugs such as antihistamines was discontinued.

[0040]

[Table 4]

Examples 4 to 6 containing the plant extract according to the present invention were all effective in improving the symptoms of atopic dermatitis, and none of the patients worsened during the application period. On the other hand, in Comparative Example 1 in which the crude drug and the plant extract were not mixed, none of the patients showed a remarkable effect, and conversely, there were four patients who became worse.

Example 7 Oil-in-Water Emulsion (1) Beeswax 0.5 (% by weight) (2) Vaseline 2.0 (3) Squalane 5.0 (4) Sorbitan sesquioleate 0.8 (5) ) Sucrose fatty acid ester 1.2 (6) 1,3-butylene glycol 10.0 (7) Glycerin 5.0 (8) Purified water 55.0 (9) Sodium carboxymethyl cellulose 20.0 (1% by weight aqueous solution) (10) Extract of Example 2 0.3 (11) Extract of Example 3 0.2 Production method: Oil phase components (1) to (4) and aqueous phase components (5) to (8) After heating to 75 ° C. to homogenize the mixture, the oil phase is added to the aqueous phase and pre-emulsified while stirring, and the component (9) heated to 70 ° C. is added, followed by emulsification with a homomixer. Cool to 40 ° C, add components (10) and (11) and mix.

Example 8 Oil-in-water emulsion (1) Polyoxyethylene (40) hydrogenated castor oil 1.0 (% by weight) (2) Glycerin 10.0 (3) 1,3-butylene glycol 5.0 (4) ) Methyl paraoxybenzoate 0.3 (5) Purified water 51.3 (6) Squalane 10.0 (7) Glyceryl monostearate 1.0 (8) Carboxyvinyl polymer (1% by weight aqueous solution) 15.0 (9 ) Sodium hydroxide (1% by weight aqueous solution) 6.0 (10) Extract of Example 1 0.2 (11) Extract of Example 2 0.1 (12) Extract of Example 3 0.1 Preparation method : The aqueous phase of (1) to (5) and the oil phase components of (6) and (7) were each heated to 75 ° C. and mixed and homogenized. Further, after adding the component (8) heated to 70 ° C., the mixture is emulsified by a homomixer. After cooling, at 40 ° C., the component (9) was added and mixed,
The components (10) to (12) are added and mixed.

Example 9 Lotion (1) Methyl parahydroxybenzoate 0.2 (% by weight) (2) Ethanol 5.0 (3) Glycerin 10.0 (4) Extract of Example 1 0.5 (5) 84.3 Purified water Production method: After dissolving (1) in (2), together with (3) and (4),
It was added sequentially to (5) and dissolved and homogenized.

Example 10 Lotion (1) Extract of Example 2 0.5 (% by weight) (2) 1,3-butylene glycol 25.0 (3) Polyoxyethylene (50) hydrogenated castor oil 0 (4) Purified water 73.5 Production method; Components (1) to (4) are mixed, dissolved and made uniform.

Example 11 Water-in-oil emulsion (1) Beeswax 2.0 (% by weight) (2) Microcrystalline wax 1.0 (3) Lanolin 2.0 (4) Liquid paraffin 30.0 (5) Stearin Aluminum acrylate 0.2 (6) Sorbitan sesquioleate 4.0 (7) Sucrose fatty acid ester 1.0 (8) Glycerin 20.0 (9) Methyl parahydroxybenzoate 0.5 (10) Purified water 38.8 (11) Extract 0.5 of Example 3 Production method: The oil phase components (1) to (6) and the aqueous phase components (7) to (11) were each heated to 75 ° C. to mix and homogenize. Add the aqueous phase to the phase and emulsify.

Example 12 Oil-in-water emulsified cream (1) Beeswax 6.0 (% by weight) (2) Cetyl alcohol 5.0 (3) Hydrogenated lanolin 8.0 (4) Squalane 30.0 (5) Stearin Monoglyceryl acid 4.0 (6) Sorbitan sesquioleate 2.0 (7) Polyoxyethylene (50) hydrogenated castor oil 2.0 (8) Purified water 32.2 (9) Methyl paraoxybenzoate 0.3 ( 10) Glycerin 5.0 (11) Ethanol 5.0 (12) Extract 0.5 of Example 1 Production method; 75 parts each of the oil phase of (1) to (7) and the component of (8)
After heating to ℃ to make the mixture uniform, the oil phase is added to (8) and emulsified. After cooling, the components (9) to (12) are dissolved and homogenized at 40 ° C. and added.

Example 13 Candy (1) White sugar 60.0 (% by weight) (2) Ginger syrup 39.5 (3) Extract 3 of Example 3 0.1 (4) Extract 0.3 of Example 1 5) Fragrance 0.1 Production method: (1) and (2) were mixed by heating, cooled, and cooled to 70%.
The components (3) to (5) are added at ℃, and the mixture is homogenized and molded.

Example 14 Tablets The barley extract obtained in Example 1 was concentrated to dryness under reduced pressure to obtain a dried product. The dried product (150 mg) was mixed with the same amount of lactose and magnesium stearate (5 g) to produce a tablet having a diameter of 10 mm and a weight of 300 mg using a tableting machine. Take one of these tablets
Twenty tablets daily for 2 weeks were taken by 20 hay fever patients. Tablets containing only lactose and magnesium stearate without containing barley extract were prepared at the same time, and were taken by 20 hay fever patients as Comparative Example 2. During the administration period, the use of other allergic drugs such as antihistamines was discontinued. The condition on the third, seventh and 14th day after the administration was answered by a questionnaire, and the antiallergic effect was evaluated. At the start of the evaluation, all subjects were allergic to hay fever and complained of itchy eyes, excessive nasal discharge, and sneezing.

[0050]

[Table 5]

As shown in Table 5, by taking the tablet of Example 14, symptoms such as itchy eyes and excessive nasal discharge were reduced. In addition, the effect was shown to be remarkable by continuous use for one week or more. In contrast, in Comparative Example 2 in which no adlay extract was blended, none of the patients had significantly improved symptoms, and 5 to 7 patients had worsened symptoms. In addition, none of the patients who used Example 14 complained of side effects such as causing drowsiness and dizziness and causing fatigue.

[0052]

Industrial Applicability As described in detail above, an antiallergic agent and a chemical mediator release containing one or more active ingredients selected from the extract of the genus Jujuda, the extract of the family Asteraceae, and the extract of the genus Lindensis. The inhibitor effectively suppresses the release of chemical mediators such as histamine, serotonin and leukotriene from mast cells and / or basophils, and cosmetics and pharmaceuticals containing the same are
It has the effect of suppressing symptoms such as itchy skin and mucous membranes, excessive nasal discharge and sneezing due to allergic reactions.

────────────────────────────────────────────────── ─── Continued on the front page (51) Int.Cl. ⁶ Identification code FI A61K 7/00 A61K 7/00 K W 7/48 7/48 // A23L 1/221 A23L 1/221 C

Claims (15)

[Claims] 1. One or two species selected from the extract of a plant belonging to the genus Zuzudama, the extract of a plant of the family Aceraceae and the extract of a plant of the genus Linus.
An antiallergic agent comprising at least one species as an active ingredient. 2. One or two selected from the extract of a plant belonging to the genus Zuzudama, the extract of a plant of the family Asteraceae, and the extract of a plant of the genus Linus.
An agent for suppressing chemical mediator release from mast cells and / or basophils, comprising at least one species as an active ingredient. 3. The method of claim 1, wherein the chemical mediator is histamine,
3. The chemical mediator release inhibitor according to claim 2, wherein the agent is one or more selected from serotonin and leukotriene. 4. The antiallergic agent and the chemical mediator release inhibitor according to claim 1, wherein the plant of the genus Jujuda is barley. 5. The antiallergic agent and the chemical mediator release inhibitor according to claim 1, wherein the plant of the family Asteraceae is a heartworm. 6. The antiallergic agent and the chemical mediator release inhibitor according to claim 1, wherein the plant of the family Asteraceae is a hamster. 7. The antiallergic agent and the chemical mediator release inhibitor according to claim 1, which comprises a barley seed extract as an active ingredient. 8. The antiallergic agent and the chemical mediator release inhibitor according to claim 1, wherein the Aspergillus oryzae is a kind of herbal medicine. 9. The antiallergic agent and the chemical mediator release inhibitor according to claim 1, wherein the linden plant is a linden flower. 10. An anti-allergic cosmetic comprising the anti-allergic agent according to claim 1 or 4 to 9 as an active ingredient. (11) An antiallergic drug containing the antiallergic agent according to (1) or (4) to (9) as an active ingredient. 12. An antiallergic food containing the antiallergic agent according to claim 1 or 4 to 9 as an active ingredient. 13. A cosmetic comprising the chemical mediator release inhibitor according to claim 2 as an active ingredient. 14. A drug containing the chemical mediator release inhibitor according to claim 2 as an active ingredient. 15. A food containing the chemical mediator release inhibitor according to claim 2 as an active ingredient.